Fusion Protein Inhibitors [MoA] - N0000175615

Pharmacologic Code	N0000175615
Pharmacologic Name	Fusion Protein Inhibitors
Pharmacologic Uses	respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

The table contains 4 products whose active ingredient are classified under the same pharmacologic class Fusion Protein Inhibitors [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	49281-574	Beyfortus	Non-Proprietary Name: Nirsevimab	Injection	Intramuscular	Sanofi Pasteur Inc.	ACTIVE
	49281-575	Beyfortus	Non-Proprietary Name: Nirsevimab	Injection	Intramuscular	Sanofi Pasteur Inc.	ACTIVE
	66658-230	Synagis	Non-Proprietary Name: Palivizumab	Injection, Solution	Intramuscular	Swedish Orphan Biovitrum Ab (publ)	ACTIVE
	66658-231	Synagis	Non-Proprietary Name: Palivizumab	Injection, Solution	Intramuscular	Swedish Orphan Biovitrum Ab (publ)	ACTIVE